

GENOMICA (PharmaMar Group) presented the comparative results of the CLART® HPV4s genotyping system for liquid cytology at the EUROGIN 2019 congress

- **The international multidisciplinary congress on HPV took place from December 4th to the 7th, in Monaco.**
- **GENOMICA presented, in an oral presentation, the comparative results of the CLART® HPV4s genotyping system, for the early detection of HPV in liquid cytologies.**

Madrid, December 10th, 2019.- GENOMICA, the molecular diagnostics company of the PharmaMar Group (MSE:PHM), presented an oral presentation at the international multidisciplinary congress on Human Papillomavirus (HPV) EUROGIN 2019, which was held from December 4th to the 7th, in Monaco. EUROGIN is a meeting point that brings together professionals and specialists to address the needs in the detection and treatment of HPV. On December 7th, **Dr Ditte Møller Ejegod, of the Department of Pathology at the University Hospital of Copenhagen (Hvidovre)**, presented the results of a comparative study on the use of CLART® HPV4s technology in SurePath™ liquid cytology, a breakthrough in the early diagnosis of HPV.

The abstract, entitled "*Comparison between BD onclarity, Roche cobas, Agena massarray HPV and GENOMICA CLART HPV4 with Surepath cervical screening samples using the VALGENT framework*" analyzes the results obtained from the genotyping of the VALGENT4 panel with four different methods. The panel consists of 1295 SurePath™ samples from the cervix and has been analyzed with: CLART® HPV4s, from GENOMICA, Onclarity™ HPV Assay (BD), HPV MassArray® (Agena Bioscience) and cobas® HPV (Roche). This study demonstrates that CLART® technology meets the international guidelines for sensitivity, specificity and reproducibility in SurePath™ cervical cancer screening specimens.



The results obtained in this multicenter study explore the possibility of using genotyping in primary cervical cancer screening in SurePath™ samples.

There are more than 100 different types of HPV, including those most at risk of developing into cervical cancer. To detect the virus, cervical cytology samples need to be collected. Nowadays, the system used is liquid cytology, since better results are obtained in the detection of precancerous cervical lesions. One of these widely used sample collection systems is SurePath™.

With GENOMICA's CLART® HPV4s technology, samples collected with this system can be genotyped from cervical cancer screening.

HPV is the most common sexually transmitted infection in the world that can cause cancer. According to statistics, between 75-80% of sexually active men and women may contract this virus at some point in their lives, accounting for 10% of cervical cancer cases in women. Currently, the technology developed by GENOMICA makes it possible to identify the specific type of HPV suffered by the patient and evaluate the risk of suffering cancer.

About cervical cancer

Cervical cancer is the fourth most common cancer in women with 570,000 new cases every year, accounting for nearly 7% of all female cancers.

The main causes of cervical cancer are human papillomavirus (HPV), of which an increasing number of subtypes have been shown to be high-risk types for cancer. Such a death rate from cervical cancer could be reduced through prevention, early diagnosis, effective detection and treatment programs.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.



PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About GENOMICA

GENOMICA is highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in Madrid, GENOMICA is 100% owned by PharmaMar. It is our mission to improve the present molecular diagnostics tools and the human identification methods through reliability and automation.

Our main objective is to maintain leadership in genomics applications within the Spanish market, and to internationally extend our activities in the area of Molecular Diagnostics by means of the design, development, automation, and commercialization of new diagnostic applications of our innovative technological platform, Clinical Arrays Technology, CLART®.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com